Randomized multicentre pilot study of LCZ696 versus irbesartan in patients with chronic kidney disease: UK Heart And Renal Protection (HARP)-III

Trial Profile

Randomized multicentre pilot study of LCZ696 versus irbesartan in patients with chronic kidney disease: UK Heart And Renal Protection (HARP)-III

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Irbesartan
  • Indications Renal failure
  • Focus Therapeutic Use
  • Acronyms UK HARP-III
  • Sponsors Novartis
  • Most Recent Events

    • 19 Sep 2016 Trial rationale, trial design and baseline data (n=414) published in the Nephrology Dialysis Transplantation.
    • 04 Mar 2016 Status changed from recruiting to active, no longer recruiting as per United Kingdom Clinical Research Network record.
    • 04 Mar 2016 Planned number of patients changed from 360 to 400 as per United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top